Related Experiment Video

Updated: Aug 20, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Development of Oncolytic Virus-Proteolysis-Targeting Chimera Conjugates for Tumor Immunotherapy

Zhixiong Gao1,2, Hanwei Huang1,2,3, Ying Zhi4

  • 1Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 155 North Nanjing Street, Heping District, Shenyang110001, China.

ACS Nano
|August 18, 2026
PubMed

Insights

This study introduces an oncolytic virus-PROTAC conjugate (BPAD) for enhanced cancer therapy. BPAD improves tumor targeting and protein degradation, boosting antitumor immune responses.

Area of Science:

  • Oncology
  • Virology
  • Molecular Biology

Background:

  • Proteolysis-targeting chimeras (PROTACs) show promise for cancer therapy but face challenges in tumor targeting and delivery.
  • Limited cellular uptake and suboptimal immune responses hinder PROTAC efficacy in vivo.
  • Oncolytic viruses (OVs) offer tumor-specific delivery but require enhancement for potent therapeutic outcomes.

Purpose of the Study:

  • To develop a novel oncolytic virus-PROTAC conjugate (BPAD) for improved targeted protein degradation in cancer.
  • To enhance the tumor-specific delivery and cellular uptake of PROTACs using OVs.
  • To investigate the synergistic effects of OV infection and PROTAC-mediated protein degradation on antitumor immunity.

Main Methods:

  • Conjugation of bromodomain-containing protein 4 (BRD4)-targeting PROTACs with oncolytic viruses (OVs) to create BPAD.
  • Evaluation of cellular uptake and tumor-selective delivery of PROTACs via OV infection.
  • Assessment of protein degradation efficiency and induction of antitumor immune responses, including type I interferon secretion and dendritic cell maturation.

Main Results:

  • BPAD demonstrated a 640-fold increase in protein degradation efficiency compared to PROTACs alone.
  • OV-mediated delivery significantly enhanced cellular uptake and tumor-specific targeting of PROTACs.
  • BPAD promoted type I interferon secretion and dendritic cell maturation, enhancing antitumor immunity prior to tumor lysis.

Conclusions:

  • The BPAD strategy represents a viable approach for creating biologically derived macromolecular PROTAC conjugates.
  • This conjugate enhances PROTAC delivery and efficacy, offering a promising platform for cancer therapy.
  • BPAD has the potential to improve the clinical translation of diverse PROTAC-based therapeutics.
Keywords:
antitumor efficacyimmunotherapyoncolytic virusproteolysis-targeting chimerassmall molecular drugs

More Related Videos

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...